← Back to Patent Explorer
US4563458A Expired / Lapsed US ⏱️ 0.0 years remaining

Substituted 4-aminomethylene-chromans and -chromenes, processes for their preparation and their use in medicaments

Assignee: Bayer AG
•
Filing: 1983-12-13
•
Granted: 1986-01-07
•
Expires: 2003-12-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to substituted 4-aminomethylene-chromans and chromens of Formula (I) infra, as well as methods for making of said chromans and chromens, compositions containing said chromans and chromens and methods for the use of said chromans, chromens and compositions containing said chromans and chromens. The compounds and compositions of the invention are useful for their circulation influencing activity.

Inventors

  • 👤 Arno Widdig
  • 👤 Hans-Joachim Kabbe
  • 👤 Andreas Knorr
  • 👤 Ulrich Benz

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 05:14
CPC Classifications
C; C07; C07D; C07D311/00; C07D407/00; C07D407/02; C07D407/12; A; A61; A61P; A61P9/00; A61P9/12; C07D311/02; C07D311/04; C07D311/58; C07D311/60; C07D311/96; C07F; C07F7/00; C07F7/02; C07F7/08; C07F7/18; C07F7/1804

Claims Analysis

Total Claims: 19
Claim 1
Independent Claim 330 words
A compound of the formula (I) ##STR140## in which --A-- represents a single bond or a double bond, and R 1 and R 2 are identical or different and represent hydrogen, C 1 -C 6 -alkyl, C 5 -C 7 -cycloalkyl, phenyl which is optionally substituted by C 1 -C 4 -alkyl, halogen and/or C 1 -C 4 -alkoxy, or C 7 -C 9 -aralkyl, whose aryl radical is optionally substituted by C 1 -C 4 -alkyl, halogen and/or C 1 -C 4 -alkoxy, or R 1 and R 2 conjointly with the enclosed C atom of the chroman ring form a 4-membered to 7-membered carbocyclic ring; R 3 to R 6 are identical or different and represent hydrogen, hydroxyl, halogen, C 1 -C 6 -alkyl, C 5 -C 7 -cycloalkyl, phenyl which is optionally substituted by C 1 -C 4 -alkyl, halogen, and/or C 1 -C 4 -alkoxy, C 7 -C 9 -aralkyl, whose aryl radical is optionally substituted by C 1 -C 4 -alkyl, halogen and/or C 1 -C 4 -alkoxy, or C 1 -C 4 -alkoxy, R 7 , R 8 , R 9 , R 10 and R 11 are identical or different and represent hydrogen or C 1 -C 6 -alkyl, X represents a single bond or methylene which is optionally monosubstituted or disubstituted by C 1 -C 4 -alkyl, oxygen or --NR 17 , wherein R 17 represents hydrogen or C 1 -C 4 -alkyl or R 17 together with R 7 forms a C 2 -alkylene ring-closing member and R 12 , R 13 , R 14 , R 15 and R 16 are identical or different and represent hydrogen, hydroxyl, halogen, C 1 -C 6 -alkyl, C 5 - or C 6 -cycloalkyl, benzyl, C 1 -C 4 -alkoxy, trifluoromethyl, or R 12 and R 13 or R 13 and R 14 together form a C 1 -C 3 -alkylenedioxy group or a --CH═CH--CH═CH-- group, and their pharmaceutically acceptable acid addition salts.
Claim 2
Dependent Claim 330 words
A compound of the formula (I) ##STR140## in which --A-- represents a single bond or a double bond, and R 1 and R 2 are identical or different and represent hydrogen, C 1 -C 6 -alkyl, C 5 -C 7 -cycloalkyl, phenyl which is optionally substituted by C 1 -C 4 -alkyl, halogen and/or C 1 -C 4 -alkoxy, or C 7 -C 9 -aralkyl, whose aryl radical is optionally substituted by C 1 -C 4 -alkyl, halogen and/or C 1 -C 4 -alkoxy, or R 1 and R 2 conjointly with the enclosed C atom of the chroman ring form a 4-membered to 7-membered carbocyclic ring; R 3 to R 6 are identical or different and represent hydrogen, hydroxyl, halogen, C 1 -C 6 -alkyl, C 5 -C 7 -cycloalkyl, phenyl which is optionally substituted by C 1 -C 4 -alkyl, halogen, and/or C 1 -C 4 -alkoxy, C 7 -C 9 -aralkyl, whose aryl radical is optionally substituted by C 1 -C 4 -alkyl, halogen and/or C 1 -C 4 -alkoxy, or C 1 -C 4 -alkoxy, R 7 , R 8 , R 9 , R 10 and R 11 are identical or different and represent hydrogen or C 1 -C 6 -alkyl, X represents a single bond or methylene which is optionally monosubstituted or disubstituted by C 1 -C 4 -alkyl, oxygen or --NR 17 , wherein R 17 represents hydrogen or C 1 -C 4 -alkyl or R 17 together with R 7 forms a C 2 -alkylene ring-closing member and R 12 , R 13 , R 14 , R 15 and R 16 are identical or different and represent hydrogen, hydroxyl, halogen, C 1 -C 6 -alkyl, C 5 - or C 6 -cycloalkyl, benzyl, C 1 -C 4 -alkoxy, trifluoromethyl, or R 12 and R 13 or R 13 and R 14 together form a C 1 -C 3 -alkylenedioxy group or a --CH═CH--CH═CH-- group, and their pharmaceutically acceptable acid addition salts.
Claim 3
Dependent Claim 175 words
A compound according to formula (I) in claim 1, in which R 1 and R 2 , are identical or different, and represent hydrogen or C 1 -C 4 -alkyl or together with the carbon atom which joins them represent a carbocyclic C 5 - or C 6 -ring, R 3 to R 6 , are identical or different, and denote hydrogen, hydroxyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy or chlorine, R 7 to R 11 , are identical or different, and represent hydrogen or C 1 -C 4 -alkyl, X represents a single bond, oxygen, methylene or --NR 17 , wherein R 17 denotes hydrogen or C 1 -C 3 -alkyl or R 17 together with R 7 forms an ethylene ring-closing member and R 12 to R 16 , are identical or different, and denote hydrogen, chlorine, cyclohexyl, C 1 -C 4 -alkyl, C 1 -C 3 -alkoxy or trifluoromethyl, or R 12 and R 13 or R 13 and R 14 together form a methylenedioxy group or --CH═CH--CH═CH--.
Claim 4
Dependent Claim 8 words
A compound of claim 1 which is 4-[γ-(3,4-Methylenedioxyphenyl)-α-methyl]-propyl-amino-methyl-2-spirocyclopentachroman.
Claim 5
Dependent Claim 8 words
A compound of claim 1 which is 4-(β-Phenylethyl)-aminomethyl-2-spirocyclopentachroman.
Claim 6
Dependent Claim 8 words
A compound of claim 1 which is 4-N-3,4-Dichlorophenylpiperazin-N'-yl-methyl-2,2-dimethyl-chromene.
Claim 7
Dependent Claim 8 words
A compound of claim 1 which is 4-β-Phenoxyethyl-aminomethyl-2-spirocyclopenta-chroman.
Claim 8
Dependent Claim 8 words
A compound of claim 1 which is 4-[γ-(2,3,4-trimethoxyphenyl)-α-methyl]-propylamino-methyl-2-spirocyclopentachoman.
Claim 9
Dependent Claim 8 words
A compound of claim 1 which is 4-[γ-(3,4-methylenedioxyphenyl)-α-methyl]propylamino-methyl-7-methoxy-2-spirocyclopentachroman.
Claim 10
Dependent Claim 8 words
A compound of claim 1 which is 4-[γ-(3,4-methylenedioxyphenyl)-α-methyl]propylamino-methyl-7-methyl-2-spirocyclopentachroman.
Claim 11
Dependent Claim 8 words
A compound of claim 1 which is 4-[γ-(2-trifluoromethyl)-α-methyl]propylamino-methyl-2-spirocyclopentachroman.
Claim 12
Dependent Claim 28 words
A pharmaceutical composition containing as an active ingredient an amount effective for combating circulatory illness of a compound according to claim 1 together with an inert pharmaceutical carrier.
Claim 13
Dependent Claim 32 words
A pharmaceutical composition containing as an active ingredient an amount effective for combating circulatory illness of a compound of claim 1 in the form of a sterile or physiologically isotonic aqueous solution.
Claim 14
Dependent Claim 17 words
A composition according to claim 11 containing from 0.5 to 90% by weight of said active ingredient.
Claim 15
Dependent Claim 26 words
A medicament in dosage unit form comprising an amount effective for combating circulatory illness of a compound according to claim 1 and an inert pharmaceutical carrier.
Claim 16
Dependent Claim 17 words
A medicament of claim 14 in the form of a tablet, pill, dragee, capsule, ampoul or suppository.
Claim 17
Dependent Claim 45 words
A method for combating circulatory illness in warm-blooded animals which comprises administering to said animals an amount effective for combating circulatory illness of an active compound according to claim 1 either alone, or in admixture with a diluent or in the form of a medicament.
Claim 18
Dependent Claim 28 words
A method according to claim 16 in which the active compound is administered in an amount of 0.001 to 10 mg per kg body weight per day intravenously.
Claim 19
Dependent Claim 28 words
A method according to claim 16 in which the active compound is administered in an amount of 0.5 to 30 mg per kg body weight per day orally.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-01-06 1989-07-08 1990-01-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-01-06 1993-07-08 1994-01-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-01-06 1997-07-08 1998-01-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag